$CELG (Celgene Corporation)

$CELG {{ '2016-07-28T13:06:55+0000' | timeago}} • Announcement

Biotechnology company $CELG reported a rise in 2Q16 earnings driven by higher product sales. Net income rose to $598.2MM or $0.75 per share from $356.2MM or $0.43 per share last year. Total revenue grew to $2.75Bil from $2.28Bil. Adjusted EPS increased to $1.44 from $1.23.

$CELG {{ '2017-07-06T14:11:20+0000' | timeago}} • Announcement

Upon closing of $CELG/$BGNE transaction, which is expected during 3Q17, BeiGene to receive upfront license fees of $263MM and $150MM in equity investment. BeiGene will also be eligible to receive up to $980MM in development, regulatory and sales milestone payments and royalties on future sales of BGB-A317, a drug used to treat cancers.

$CELG {{ '2017-07-06T14:08:05+0000' | timeago}} • Announcement

$CELG enters into a collaborative agreement with biopharma company $BGNE to treat tumor cancers. Celgene will acquire 32.7MM or 5.9% of BeiGene's ordinary shares at $4.58 per share. BeiGene to acquire Celgene's commercial operations in China. BeiGene will also license and assume commercial responsibility for Celgene's approved therapies in China.

$CELG {{ '2017-06-19T12:38:44+0000' | timeago}} • Announcement

Pharma firm $CELG said it would present data from various clinical studies evaluating its  investigational agents for the treatment of blood cancer, at the European Hematology Association’s annual meeting to be held in Madrid, Spain, from June 22 to 25. The data will support the role of Celgene’s therapies as the foundation of myeloma research.

$CELG {{ '2017-06-19T10:48:16+0000' | timeago}} • Announcement

$CELG announced results from interim analysis of Magnify, a phase 3b, randomized, open-label, multicenter study of Revlimid (lenalidomide) plus rituximab combination therapy in patients with relapsed or refractory marginal zone lymphoma (MZL). Lymphoma a group of blood cell tumors that develop from lymphocytes (a type of white blood cell).

$CELG {{ '2017-06-14T11:57:50+0000' | timeago}} • Announcement

Celgene International Sarl, a subsidiary of $CELG, announced results from the phase 2a SLE-001 trial evaluating CC-220, its investigational, oral immunomodulatory compound. A trend toward greater improvement with CC-220 treatment compared with placebo in multiple measures of disease activity was observed in patients with lupus.

$CELG {{ '2017-06-06T17:22:32+0000' | timeago}} • Announcement

Pharma companies $CELG and $AGIO said their phase-1 study on leukemia drug Idhifa in patients with relapsed or refractory acute myeloid leukemia and isocitrate dehydrogenase-2 mutation demonstrated an overall response rate of 40.3%. The outcome reinforces the potential for Idhifa as a first-in-class therapy for such patients.

$BLUE {{ '2017-06-05T16:32:59+0000' | timeago}} • Announcement

$BLUE and $CELG said updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell therapy, in 18 patients with relapsed/refractory multiple myeloma will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

$CELG {{ '2017-05-22T12:25:38+0000' | timeago}} • Announcement

$CELG announced that its phase III RADIANCE trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR).

$CELG {{ '2017-04-27T14:45:31+0000' | timeago}} • Webcast

$CELG's pipeline includes around 14 unique molecules that are in late-stage development or in proof-of-concept stage development between 2017-2022 and provide opportunity for diversification. $CELG forecasts about $1Bil in revenue from about 10 of these molecules with the other 4 being multi-billion dollar opportunities.

$CELG {{ '2017-04-27T14:30:05+0000' | timeago}} • Webcast

During 1Q17, $CELG saw contraction in the market for OTEZLA, as it saw increased gross-to-net adjustments related to contracts. This gives the company access to up to 100MM insured lives going forward. $CELG also saw minimal drawdown on the inventory. OTEZLA continues to grow market share and gained more than 40% of new patients.

$CELG {{ '2017-04-27T12:17:26+0000' | timeago}} • Infographic

$CELG Celgene Corporation Earnings AlphaGraphics: Q1 2017 Highlights

$CELG {{ '2017-04-27T12:06:27+0000' | timeago}} • Announcement

For 2017, $CELG expects total revenue to be $13-13.4Bil. Diluted EPS is expected to be $5.95-6.29 while adjusted diluted EPS is expected to be $7.15-7.30. Operating margin is expected to be approx. 46% while adjusted operating margin is expected to be 57%.

$CELG {{ '2017-04-27T12:02:21+0000' | timeago}} • Announcement

$CELG reported an increase in 1Q17 earnings helped by higher revenues. Net income was $941MM or $1.16 per share compared to $801MM or $0.99 per share in 1Q16. Total revenue was $2.96Bil, an 18% increase compared to 1Q16. Net product sales were $2.95Bil, up 18% from 1Q16.

$CELG {{ '2017-02-24T13:15:42+0000' | timeago}} • Announcement

$CELG said its President and COO Jacqualyn Fouse has decided to retire from the company effective June 30, 2017. She will continue to serve as President and COO until April 1, and through June 30, she will serve as a strategic advisor to the management team. Jackie will not stand for reelection to BoD at the upcoming Annual Meeting in June.

$CELG {{ '2017-02-24T13:14:32+0000' | timeago}} • Announcement

$CELG said President and COO Jacqualyn Fouse has decided to retire from the company effective June 30, 2017. The company promoted Scott Smith to President and COO, effective April 1, 2017, and the promotion of Terrie Curran to President, Global Inflammation & Immunology (I&I) Franchise, effective April 1, 2017.

$CELG {{ '2017-01-26T17:15:18+0000' | timeago}} • Announcement

$CELG agreed to buy privately-held Delinia, Inc., a biotechnology company developing novel therapeutics for autoimmune diseases. $CELG will make an initial payment of $300MM. Delinia shareholders will be eligible to receive up to an additional $475MM in contingent payments. The transaction is expected to close in 1Q17.

$CELG {{ '2017-01-26T16:41:09+0000' | timeago}} • Webcast

$CELG said REVLIMID had a 24% annual revenue growth in U.S. during 4Q16, but was lower in Europe due to a large Russian tender. Excluding the Russian tender, REVLIMID had a valuable growth in Europe both from a volume and sales perspective, said the company.

$CELG {{ '2017-01-26T16:30:36+0000' | timeago}} • Webcast

Regarding commercialization of Ozanimod, $CELG said that currently majority of its activity is in the clinical development, clinical operations and medical affairs of Ozanimod.

$CELG {{ '2017-01-26T15:44:41+0000' | timeago}} • Webcast

$CELG said that over the next two years, it expects data from 19 phase III trials to become available. During the same time period, the company expects to advance at least nine novel agents to pivotal trials and gain increasing clarity into the profiles of 14 new products.

$CELG {{ '2017-01-26T15:03:33+0000' | timeago}} • Announcement

During 4Q16, sales of $CELG's multiple myeloma drug Revlimid rose 16% to $1.80Bil and that of Pomalyst/imnovid rose 29% YoverY to $378MM. Sales of Otezla during the quarter rose 67% to $305MM. Sales of the breast cancer treating drug Abraxane fell 1% to $266MM.

Recent Transcripts

ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
UNH (UnitedHealth Group Incorporated)
Tuesday, July 18 2017 - 12:45pm
USPH (US Physical Therapy Inc.)
Thursday, June 29 2017 - 2:30pm
ARRY (Array BioPharma Inc.)
Wednesday, May 10 2017 - 1:00pm
VCEL (Vericel Corporation)
Wednesday, May 10 2017 - 12:00pm
ATHX (Athersys, Inc.)
Tuesday, May 9 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
MNK (Mallinckrodt Public Limited Company)
Monday, May 8 2017 - 12:30pm
SNN (Smith & Nephew plc)
Friday, May 5 2017 - 7:30pm
SEM (Select Medical Holdings Corporation)
Friday, May 5 2017 - 1:00pm
ZGNX (Zogenix, Inc.)
Thursday, May 4 2017 - 8:30pm
CBM (Cambrex Corporation.)
Thursday, May 4 2017 - 12:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
ARQL (ArQule Inc.)
Wednesday, May 3 2017 - 1:00pm
WCG (WellCare Health Plans, Inc.)
Wednesday, May 3 2017 - 12:00pm
EXEL (Exelixis, Inc.)
Monday, May 1 2017 - 9:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, April 27 2017 - 1:00pm
VAR (Varian Medical Systems, Inc.)
Wednesday, April 26 2017 - 9:00pm

AlphaGraphics you may like